Expectations trend
FY2028 · fiscal year ending 2028-02-28 · fmp
Sono-Tek Corp (SOTK)
NASDAQInformation TechnologyIndustrial - MachinerySnapshot 2026-11-05
$4.34-3.77%
Close 2026-11-05 · 1-day change
NASDAQInformation TechnologyIndustrial - MachinerySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.14 → 0.18 EPS · FY ending Feb 28, 2028 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for SOTK yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve cash from operating activities | Cash from operations improved from negative $177K to positive $3.14M in the same period. | Improving | cash from operations falls below zero in any quarter through 2026-Q4 | Cash from operations: $1.162M FY2027-Q2; GAAP. Published target: >= $3.14 million cash from operations in 2026-Q4. The stored target says 2026-Q4; this source reports FY2027-Q2. Fiscal/calendar alignment needs review. Oct 14, 20261,161,691 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-02-28 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a small-cap growth business with improving profitability and a fast-growing medical segment. Its long-term thesis is intact, but execution risk is elevated and the evidence snapshot gives medium confidence.
SOTK carries a durable premium versus peers, while the valuation measure has risen recently. The expectations gap is negative, suggesting expectations are not fully matched by the current setup; the priced-in assessment calls the premium justified, with low fragility.
Near-term results may remain uneven: SOTK missed earnings in October, and the snapshot flags a higher-than-usual risk of another miss. Over the multi-year view, revenue growth has been modest, while margins, operating income, and medical sales have strengthened; management remains on track with its stated priorities.
A guidance cut on the next call would be a meaningful negative and could lead analysts to lower estimates. The favorable case depends partly on lower interest rates and steadier results from other technology companies, which could ease pressure on the sector.
For the next 1 to 3 years, the thesis rests on continued margin gains and medical growth outweighing modest overall revenue growth and uneven quarterly execution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain profit margins near current levels | A supporting condition in Sono-Tek Corp's published investment case. The stated target is maintain profit margins near recent levels. | Improving | profit margins decline significantly below recent levels in next 4 quarters | Net margin: 7% FY2027-Q2; GAAP. Published target: maintain profit margins near recent levels. Target percentage unit is not explicit. Oct 14, 20267.000827 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve modest revenue growth | A primary condition in Sono-Tek Corp's published investment case. The stated target is >= $5.61 million revenue in 2026-Q4. | Intact | revenue falls below $5.03 million in any quarter through 2026-Q4 | Revenue: $5.232M FY2027-Q2; GAAP. Published target: >= $5.61 million revenue in 2026-Q4. The stored target says 2026-Q4; this source reports FY2027-Q2. Fiscal/calendar alignment needs review. Oct 14, 20265,232,153 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “These results reflect disciplined execution across our operations and continued progress with our strategy of focusing on higher-value production systems in advanced technology markets, particularly medical devices.” “This outlook reflects the timing of several large, higher-value production platform orders, which can result in increased quarter-to-quarter variability as these systems become a larger portion of our business.” Delivery assessment Nov 5, 2026 |
Stable management and execution | A supporting condition in Sono-Tek Corp's published investment case. The stated target is management remains stable with no major disruptions. | Intact | major management departures or disruptions occur | Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.10 → $0.18 · observed estimates
$0.02B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-07-25 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-07-26 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-07-27 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-07-28 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-07-29 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-07-30 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-07-31 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-01 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-02 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-03 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-04 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-05 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-06 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-08 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-09 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-10 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-12 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-13 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-14 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-15 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-16 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-17 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-18 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-19 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-20 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-21 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-22 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-23 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-24 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-25 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-26 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-27 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-28 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-29 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-30 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-08-31 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-01 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-02 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-03 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-04 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-05 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-06 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-07 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-08 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-09 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-10 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-11 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-12 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-13 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-14 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-15 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-16 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-17 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-18 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-19 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-20 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-21 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-22 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-23 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-24 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-25 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-26 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-27 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-28 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-29 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-09-30 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-10-01 | $0.10 | $23,940,818 | 1 / 1 |
| 2026-10-02 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-03 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-04 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-05 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-06 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-07 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-08 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-09 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-10 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-11 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-12 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-13 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-14 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-15 | $0.14 | $25,604,318 | 1 / 1 |
| 2026-10-16 | $0.18 | $26,472,355 | 1 / 1 |
| 2026-10-17 | $0.18 | $26,472,355 | 1 / 1 |
| 2026-10-18 | $0.18 | $26,472,355 | 1 / 1 |
| 2026-10-19 | $0.18 | $26,472,355 | 1 / 1 |
| 2026-10-20 | $0.18 | $26,472,355 | 1 / 1 |
| 2026-10-21 | $0.18 | $26,472,355 | 1 / 1 |
| 2026-10-22 | $0.18 | $26,472,355 | 1 / 1 |
| 2026-10-23 | $0.18 | $26,472,355 | 1 / 1 |
| 2026-10-24 | $0.18 | $26,472,355 | 1 / 1 |
| 2026-10-25 | $0.18 | $26,472,355 | 1 / 1 |
| 2026-10-26 | $0.18 | $26,472,355 | 1 / 1 |
| 2026-10-27 | $0.18 | $26,472,355 | 1 / 1 |
| 2026-10-28 | $0.18 | $26,452,354 | 1 / 1 |
| 2026-10-29 | $0.18 | $26,452,354 | 1 / 1 |
| 2026-10-30 | $0.18 | $26,452,354 | 1 / 1 |
| 2026-10-31 | $0.18 | $26,452,354 | 1 / 1 |
| 2026-11-01 | $0.18 | $26,452,354 | 1 / 1 |
| 2026-11-02 | $0.18 | $26,452,354 | 1 / 1 |
| 2026-11-03 | $0.18 | $26,452,354 | 1 / 1 |
| 2026-11-04 | $0.18 | $26,452,354 | 1 / 1 |
| 2026-11-05 | $0.18 | $26,452,354 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 1 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.